Showing 8131-8140 of 9548 results for "".
- IPC, Others Call for Creation of Worldwide Psoriasis Databasehttps://practicaldermatology.com/news/ipc-others-call-for-creation-of-worldwide-psoriasis-database/2458055/A new report calls for the creation of a web-based Global Psoriasis Atlas (GPA) database that will document the prevalence and incidence of psoriasis worldwide. The report, entitled "Global State of Psoriasis Epidemiology: A Workshop Report,
- Two Galderma Rosacea Therapies Work Well Togetherhttps://practicaldermatology.com/news/two-galderma-rosacea-therapies-work-well-together/2458061/Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCe
- GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologicshttps://practicaldermatology.com/news/gbi-research-global-dermatology-pipeline-to-see-shift-toward-increased-use-of-biologics/2458071/The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of the pipeline dominated by generics and biosimilars, according to GBI Research. The company
- The Prescription Dermatological Drugs Market Forecasthttps://practicaldermatology.com/news/the-prescription-dermatological-drugs-market-forecast/2458079/The "World Prescription Dermatological Drugs Market, 10th Edition" report, now available from Research and Markets shows the field
- National Psoriasis Foundation Honors Research Award Recipients at Biennial Research Symposiumhttps://practicaldermatology.com/news/national-psoriasis-foundation-honored-research-award-recipients-at-biennial-research-symposium/2458078/The National Psoriasis Foundation (NPF) recognized two distinguished research professionals for their unique impact on psoriatic disease research during the 2017 NPF Research Symposium.
- Researchers Close in on Cause of Inflammation in Rosaceahttps://practicaldermatology.com/news/researchers-close-in-on-cause-of-inflammation-in-rosacea/2458091/Once developed, therapies that block TRPV4 may help treat or prevent inflammation in patients with rosacea, according to new research funded by the National Rosacea Society (NRS). In earlier research, the team l
- DermTech Secures Billing Codes for its Proprietary Melanoma Testhttps://practicaldermatology.com/news/dermtech-secures-billing-codes-for-its-proprietary-melanoma-test/2458115/The American Medical Association (AMA) has granted DermTech, Inc. Category 1, Tier 2 Molecular Pathology procedure codes related to its proprietary test for the detection of melanoma related gene expression. The company has secured this Common Procedural Terminology (CPT) coding for LINC and PRAM
- Valeant to Sell Obagi Medical Products Business for $190 Mhttps://practicaldermatology.com/news/valeant-to-sell-obagi-medical-products-business-for-190-m/2458117/Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic ma
- No Need to Delay Certain Skin Procedures for Isotretinoin Patientshttps://practicaldermatology.com/news/no-need-to-delay-certain-skin-procedures-for-isotretinoin-patients/2458140/New consensus recommendations set the record straight on the timing of skin procedures for patients taking isotretinoin. After reviewing 32 relevant publications, the authors found “insufficient evidence” to support delaying manual dermabrasion, superficial chemical peels
- Thumbs Down for Neothetics, Inc.'s LIPO-202; Stock Plummetshttps://practicaldermatology.com/news/thumbs-down-for-neothetics-incs-lipo-202/2458145/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares droppe